Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 82,402
  • Shares Outstanding, K 207,510
  • Annual Sales, $ 176,230 K
  • Annual Income, $ -257,830 K
  • 60-Month Beta 1.24
  • Price/Sales 0.47
  • Price/Cash Flow 10.95
  • Price/Book 1.48
Trade SGMO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.32
  • Most Recent Earnings $-0.27 on 05/09/24
  • Next Earnings Date 08/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 178.05% ( -51.20%)
  • Historical Volatility 108.98%
  • IV Percentile 42%
  • IV Rank 16.71%
  • IV High 1,058.08% on 11/14/23
  • IV Low 1.50% on 08/15/23
  • Put/Call Vol Ratio 0.13
  • Today's Volume 101
  • Volume Avg (30-Day) 622
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 28,485
  • Open Int (30-Day) 23,941

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate -0.09
  • Low Estimate -0.20
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +56.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3040 +30.63%
on 07/05/24
0.4820 -17.61%
on 06/24/24
-0.0241 (-5.72%)
since 06/18/24
3-Month
0.3040 +30.63%
on 07/05/24
0.7000 -43.27%
on 05/17/24
-0.1144 (-22.37%)
since 04/19/24
52-Week
0.2911 +36.41%
on 11/13/23
1.5285 -74.02%
on 07/20/23
-1.0679 (-72.89%)
since 07/19/23

Most Recent Stories

More News
Sangamo: Q1 Earnings Snapshot

Sangamo: Q1 Earnings Snapshot

SGMO : 0.3971 (-1.49%)
Sangamo: Q4 Earnings Snapshot

Sangamo: Q4 Earnings Snapshot

SGMO : 0.3971 (-1.49%)
Sangamo: Q3 Earnings Snapshot

Sangamo: Q3 Earnings Snapshot

SGMO : 0.3971 (-1.49%)
Sangamo: Q2 Earnings Snapshot

Sangamo: Q2 Earnings Snapshot

SGMO : 0.3971 (-1.49%)
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at the...

SGMO : 0.3971 (-1.49%)
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including a strategic pipeline prioritization and restructuring, and reported certain...

SGMO : 0.3971 (-1.49%)
Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday,...

SGMO : 0.3971 (-1.49%)
Sangamo: Q4 Earnings Snapshot

Sangamo: Q4 Earnings Snapshot

SGMO : 0.3971 (-1.49%)
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results.

SGMO : 0.3971 (-1.49%)
Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data as of the October 20, 2022 cutoff date from the Phase 1/2 STAAR clinical study evaluating...

SGMO : 0.3971 (-1.49%)

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 0.4918
2nd Resistance Point 0.4630
1st Resistance Point 0.4300
Last Price 0.3971
1st Support Level 0.3682
2nd Support Level 0.3394
3rd Support Level 0.3064

See More

52-Week High 1.5285
Fibonacci 61.8% 1.0558
Fibonacci 50% 0.9098
Fibonacci 38.2% 0.7638
Last Price 0.3971
52-Week Low 0.2911

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar